Abstract
As recently shown, angiogenesis is the most reliable marker of breast cancer invasiveness. Unfortunately it must be assessed by immunohistochemistry on tissue specimens. We have used technetium-99m sestamibi, a marker of regional blood flow in other organs that often but not always images breast cancer, to assess the invasiveness of this tumour. Nineteen patients, ten with nodal metastases and nine without any metastases, were studied with 99mTc-sestamibi scintigraphy before operation. Angiogenesis was quantitatively assessed by immunohistochemical staining of endothelia for factor VIII. All the node-positive (N+) patients at surgical revision showed a positive 99mTc-sestamibi scan of the primary tumour and all the N-patients were negative. Nine out of ten N+ and sestamibi-positive tumours showed more than 135 microvessels/mm2 and one showed 99 microvessels/mm2; by contrast there were 71.6±12.1 microvessels/mm2 in the nine N- and sestamibi-negative tumours. Our study suggests that 99mTc-sestamibi is a marker of breast cancer invasiveness: its uptake is related to angiogenesis and, possibly, to oxidative metabolism of the tumour.
This is a preview of subscription content, log in via an institution to check access.
References
Allan SM. The prospects for imaging lymph nodes in breast cancer. Eur J Nucl Med 1992; 19: 836–837.
Weidner N, Semple JP, Welch WR, et al. Tumor angiogenesis and metastasis. Correlation in invasive breast carcinoma. N Engl J Med 1991; 324: 1–8.
Horak ER, Russel L, Klenk N, et al. Angiogenesis, assessed by platelet/endothelial cell adhesion molecule antibodies, as indicator of node metastases and survival in breast cancer. Lancet 1992; 340: 1120–1124.
Kao CH, Yang MD, Wang SJ, et al. The Tc-99m MIBI scintigraphy in the evaluation of mass abnormalities of the breast [abstract]. Eur J Nucl Med 1993; 20: 979.
Scopinaro F, Schillaci O, Di Macio L, et al. 99m-Tc sestamibi scan in breast cancer [abstract]. Eur J Nucl Med 1993; 20: 979.
Mahadevan V, Hart IR. Metastasis and angiogenesis. Acta Oncol 1990; 29:97–103.
Ennis BW, Lippman ME, Dickson RB. The EGF receptor system as a target for antitumor therapy. Cancer Invest 1991; 9: 353–362.
Crane P, La Liberte' R, Heminway S, et al. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur J Nucl Med 1993; 20: 20–23.
Delmon-Moingeon LI, Piwnica-Worms D, Van Den Abbeele AD, et al. Uptake of the cation hexakis (2-methoxy isobutylisonitrile)-technetium-99m by human carcinoma cell lines in vitro. Cancer Res 1990; 50: 2148–2202.
Slomsman Do, Pugin J. Lack of correlation between tritiated deoxyglucose, thallium-201 and technetium-99m-MIBI cell incorporation under various cell stresses. J Nucl Med 1994; 35:120–126.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Scopinaro, F., Schillaci, O., Scarpini, M. et al. Technetium-99m sestamibi: an indicator of breast cancer invasiveness. Eur J Nucl Med 21, 984–987 (1994). https://doi.org/10.1007/BF00238124
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF00238124